Walleye Capital LLC raised its stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) by 53.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 20,455 shares of the company’s stock after acquiring an additional 7,117 shares during the period. Walleye Capital LLC’s holdings in Zentalis Pharmaceuticals were worth $944,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in ZNTL. Captrust Financial Advisors increased its holdings in Zentalis Pharmaceuticals by 15,160.0% in the 1st quarter. Captrust Financial Advisors now owns 763 shares of the company’s stock valued at $35,000 after purchasing an additional 758 shares during the last quarter. US Bancorp DE raised its holdings in shares of Zentalis Pharmaceuticals by 378.9% in the 1st quarter. US Bancorp DE now owns 1,451 shares of the company’s stock valued at $67,000 after buying an additional 1,148 shares during the period. Point72 Hong Kong Ltd acquired a new position in Zentalis Pharmaceuticals during the 1st quarter worth about $72,000. Advisor Group Holdings Inc. boosted its holdings in Zentalis Pharmaceuticals by 1,082.5% during the 4th quarter. Advisor Group Holdings Inc. now owns 1,218 shares of the company’s stock valued at $102,000 after acquiring an additional 1,115 shares during the period. Finally, Prospera Financial Services Inc acquired a new position in Zentalis Pharmaceuticals in the 1st quarter valued at about $104,000.
Insiders Place Their Bets
In related news, COO Kevin D. Bunker sold 1,710 shares of the company’s stock in a transaction dated Wednesday, July 13th. The stock was sold at an average price of $30.02, for a total value of $51,334.20. Following the completion of the sale, the chief operating officer now directly owns 108,290 shares of the company’s stock, valued at approximately $3,250,865.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Zentalis Pharmaceuticals news, President Cam Gallagher sold 12,500 shares of Zentalis Pharmaceuticals stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $25.26, for a total value of $315,750.00. Following the transaction, the president now directly owns 454,385 shares in the company, valued at $11,477,765.10. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Kevin D. Bunker sold 1,710 shares of the stock in a transaction dated Wednesday, July 13th. The stock was sold at an average price of $30.02, for a total transaction of $51,334.20. Following the sale, the chief operating officer now owns 108,290 shares of the company’s stock, valued at approximately $3,250,865.80. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 44,210 shares of company stock valued at $1,268,834. 19.90% of the stock is currently owned by insiders.
Zentalis Pharmaceuticals Stock Down 3.9 %
Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Rating) last issued its earnings results on Tuesday, August 9th. The company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.21) by ($0.13). As a group, sell-side analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -4.78 EPS for the current year.
Analysts Set New Price Targets
Several analysts have recently issued reports on ZNTL shares. Morgan Stanley reduced their price target on shares of Zentalis Pharmaceuticals from $95.00 to $60.00 and set an “overweight” rating on the stock in a research report on Thursday, August 11th. Cowen initiated coverage on shares of Zentalis Pharmaceuticals in a report on Tuesday, July 12th. They set an “outperform” rating on the stock. Cowen started coverage on shares of Zentalis Pharmaceuticals in a research note on Tuesday, July 12th. They issued an “outperform” rating for the company. HC Wainwright reduced their price objective on Zentalis Pharmaceuticals from $120.00 to $55.00 and set a “buy” rating on the stock in a research note on Wednesday, August 10th. Finally, SVB Leerink lowered their target price on Zentalis Pharmaceuticals from $67.00 to $42.00 and set an “outperform” rating for the company in a research note on Wednesday, August 10th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Zentalis Pharmaceuticals currently has an average rating of “Buy” and an average target price of $61.38.
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.
- Get a free copy of the StockNews.com research report on Zentalis Pharmaceuticals (ZNTL)
- Oracle’s Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.